Solving the problem of drug disposal
|
|
- Anastasia Amberlynn Rice
- 6 years ago
- Views:
Transcription
1 Solving the problem of drug disposal
2 Summary Why We Exist Who We Are To prevent the diversion of prescription opioids and to reinforce safe disposal of all medications through education and awareness A group of committed scientists and entrepreneurs who want to help solve the opioid abuse epidemic by establishing the gold standard for medication disposal What We Do How We Do It When Is It Available? Provide a unique cross-linking technology that is added to water which safely renders medications unusable and inconsumable. This is accomplished by using a proprietary blend of powders, which are a safe blend of chemical polymers listed by the FDA as safe and biodegradable By sharing with the consumer a technology that s as easy as adding a sweetener packet to iced tea or a flower food packet to a vase of flowers September 2017
3 Worst Drug epidemic in American History! Market is lacking non-toxic consumer facing medications disposal methods. Problem Purpose Raising awareness by highlighting safe and simple to use consumer facing medication disposal alternatives that captures unused medications in a non-toxic viscous environment, rendering it inaccessible removing it from the ecosystem of misuse, abuse & diversion. Goal Expand pharmacy services and educating patients with defined programs that mirror diabetes and hearth health initiatives, targeting the importance of proper medication disposal, through safe and cost-effective solutions.
4 Abuse Deterrent Experience John W. Holaday, Ph.D., is scientist with decades of experience in neuroscience, oncology and immunology. Dr. Holaday was the former CEO of QRxPharma Limited (QRX-ASX) and the co-founder of Medicis (MRX- NYSE) and served at the Walter Reed Army Institute of Research as Captain, US Army and Chair of Neuropharmacology Brand. Dr. Holaday holds a BS and MS from the University of Alabama, and PhD from the University of California, San Francisco School of Medicine. Edward Rudnic, Ph.D., is a scientist and pharmaceutical executive with an extensive background in the biopharmaceutical industry. Dr. Rudnic was founder, chairman and CEO of MiddleBrook Pharmaceuticals (Nasdaq: MBRK, previously Advancis; Nasdaq: AVNC) and was Sr. VP, Development and Technical Operations for Shire Laboratories, where he was the lead inventor of Carbatrol and co-inventor of Adderall XR. Dr. Rudnic has been named lead inventor or co-inventor of 54 issued U.S. patents and numerous related international patents. Dr. Rudnic holds a BS in Pharmacy, a MS in Pharmaceutics and a PhD in pharmaceutical Sciences from the University of Rhode Island. Marcus Schestopol, is a pharmaceutical development chemical engineer with over 15 years of experience in pharmaceutical CMC product development. Marcus received his Chemistry degree from Emory University and his Chemical Engineering degree from the Georgia Institute of Technology.
5 The Solution: DisposeRx TM 1: Open vial 2: Add warm tap water until vial is 2/3 full 3: Add DisposeRx Powder & shake for ~30 seconds, contents solidifies in <10 min. Pills + DisposeRx + Water = 100% effectiveness Proprietary, patented technology made of solidifying cross-linking chemical polymers to sequester all medications All materials used in DisposeRx are safe and listed in the FDA s Inactive Ingredient Database. DisposeRx crosslinking polymers are found in foods, oral drug products, are safe to ingest if accidentally exposed, and environmentally-friendly. Video Link:
6 DisposeRx Sequestration DisposeRx formulated testing Biodegradable matrix DisposeRx formulated its products to be compliant with evolving recommended governmental standards including DEA guidelines (Dec. 21, 2012, 21 CFR Subpart C, ). According to the DEA the method of destruction shall be consistent with the purpose of rendering all controlled substances to a non-retrievable state in order to prevent diversion of any such substance to illicit purposes and to protect the public health and safety.
7 Product Review At DisposeRx, our team is focused on stopping the opioid epidemic at the home medicine cabinet, preventing the cycle of environmental pollution, addiction, overdose and death. DisposeRx was designed especially for site-of-use disposal (the action of sequestering pharmaceutical ingredients within the vial in which the prescription was dispensed), uniquely capturing prescription drugs within the prescription vial, users are empowered with a best-in-class drug disposal solution. The disruptive cross-linking polymer blend, embraces safe and easy to understand user directions, providing the only prescription drug disposal solution which permanently captures drugs in a non-divertible and biodegradable gel. Our biodegradable solid is manufactured with components that are safe enough to be eaten. The disposal composition material, when combined with water and medicaments, forms a gel substance of high viscosity that it is not easily pourable, transferable, or mixable, and remains in the container in which it is formed. DisposeRx is able to provide homes and communities with a process where they can effortlessly be a part of the solution, breaking the chain of illicit prescription drug access and curbing our nation s opioid epidemic.
8 Extraction Data Data for all solvent extraction conditions are presented in this section. The mean percent (w/w) of Oxycodone recovered from the filtrate during each duplicate analyses was calculated and graphed. Specifically, the percent recovery of Oxycodone relative to the initial quantity of Oxycodone added was calculated (see Figure 1). Note: 40 tablets of 5 mg Oxycodone HCl equates to: 200 mg (0.200 g) Oxycodone HCl and mg ( g) Oxycodone free base. All results are reported as free base. A range of 0 8% of Oxycodone was recovered from filtrates across all conditions; this equates to approximately mg ( g) of Oxycodone. Gel after settling for minutes after mixing Test Product with water; white tablet particulate evident
9 Solvent Extraction Sample ID Oxycodone Added (mg) Filtrate Recovered (ml) Average Filtrate Recovered (ml) Oxycodone Recovered (mg) LC-MS/MS value (mcg/ml) Pre-filtration Mass (g) % Oxycodone Recovered Relative to Initial Oxycodone Added Average % Oxycodone Recovered Relative to Initial Oxycodone Added % Oxycodone Recovered Relative to Pre-filtration Mass Average % Oxycodone Recovered Relative to Pre-filtration Mass 1A B A B A % B A B A % % 5B % 6A % % 6B % 7A % % 7B % When considering the disposal of critical drugs of abuse including opioids (e.g. Oxycodone), it is essential that these substances are discarded in such a way that drug abusers are unable to access the material for abuse purposes. The DisposeRx product possesses multiple deterrence mechanisms which render the resulting material less amenable to abuse; these include the formation of a gelatinous mass upon mixing with pharmaceuticals, and the production of highly viscous solutions upon extracting the material with common household solvents. Sample preparation, Solvent extraction, Filtration and Quantitation data collected during study.
10 Thank you Wm Simpson, President 135 West Illinois Ave., Suite 1 Southern Pines, NC T/ (844) E/ wsimpson@disposerx.com
Disposal of leftover and expired drugs by sequestration in cross-linking. polymers
Disposal of leftover and expired drugs by sequestration in cross-linking Introduction: polymers Marcus Schestopol and John Holaday, PhD DisposeRx, Inc., 6502 Hillmead Rd., Bethesda, MD 20817 Many medicaments,
More informationCopyright 2018 DisposeRx, Inc. All rights reserved.
30 seconds breaks the chain of abuse and pollution!!! The problem starts at home; the solution: DisposeRx has developed a simple to use, inhome disposal solution for unused, unwanted, expired and/or off-therapy
More informationReference ID: NDA was approved on December 12, The product was not formulated with properties to deter abuse,
tablets (NDA 020553). 1 According to Purdue, the reformulated OxyContin (OCR) had controlled-release features that would be less easily compromised by tampering than the original OxyContin (OC), and thereby
More informationPerformance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)
Performance of North Carolina's System for Monitoring Prescription Drug Abuse Session Law 2015-241, Section 12F.16.(q) Report to the Joint Legislative Oversight Committee on Health and Human Services and
More informationDeath, Detection, Diversion, & Disposal: Utah Case Study
http://www.medicationdisposal.utah.gov/ ww.useonlyasdirected.org Death, Detection, Diversion, & Disposal: Utah Case Study Presented by: Erin Johnson, MPH, Utah Department of Health Elizabeth Sollis, CSW,
More informationSUBHEAD GOES HERE. Addressing Tennessee s Opioid Crisis. Natalie A. Tate, PharmD Vice President, Pharmacy
SUBHEAD GOES HERE Addressing Tennessee s Opioid Crisis Natalie A. Tate, PharmD Vice President, Pharmacy Our opioids story Our approach Our response to neonatal abstinence syndrome Facts and faces of opioid
More informationMichael M. Miller, MD, FASAM, FAPA
Michael M. Miller, MD, FASAM, FAPA mmiller@rogershospital.org Medical Director, Herrington Recovery Center (HRC) Rogers Memorial Hospital Oconomowoc, Wisconsin Vice Speaker Wisconsin Medical Society Clinical
More informationPennsylvania Prescription Drug Monitoring Program Trends,
DEA Intelligence Report Brief DEA-PHL-DIR-006-17 Pennsylvania Prescription Drug Monitoring Program Trends, 2014-2015 December 2016 1 Executive Summary The abuse and diversion of pharmaceutical drugs, particularly
More informationChairwoman Bono Mack, Vice-Chairwoman Blackburn, Ranking Member Butterfield and
United States House of Representatives Committee on Energy and Commerce Subcommittee on Commerce, Manufacturing and Trade Hearing on Chairwoman Bono Mack, Vice-Chairwoman Blackburn, Ranking Member Butterfield
More informationAligning Market Objectives and Policy for National Public Health
Abuse-Deterrent Formulations Summit March 7, 2017 Alexandria, Virginia Aligning Market Objectives and Policy for National Public Health Shruti Kulkarni, Esq. Outside Counsel Twitter: @claad_coalition CLAAD
More informationIn Vitro Considerations for Development Abuse Deterrent Dosage Forms
In Vitro Considerations for Development Abuse Deterrent Dosage Forms Presentation to AAPS Annual Meeting Nov 3, 2014 Nagesh Bandi, Ph.D. Global CMC New Products Pfizer Inc. 1 Disclaimer The thoughts and
More informationOpioid Abuse in Iowa Rx to Heroin. Iowa Governor s Office of Drug Control Policy January 2016
1 Opioid Abuse in Iowa Rx to Heroin Iowa Governor s Office of Drug Control Policy January 2016 Why Is This Important? 2 3 National Rx Painkiller Trends CDC, 2013 4 National Rx-Heroin Trends NIH, 2015 5
More informationEgalet Corporate Presentation
Egalet Corporate Presentation Specialty Pharmaceutical Company Focused on Pain 1 NASDAQ: EGLT Forward-Looking Statements Statements included in this presentation that are not historical in nature are "forward-looking
More informationRule Governing the Prescribing of Opioids for Pain
Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This
More informationNaloxone and Combating the Opioid Epidemic
Objectives Naloxone and Combating the Opioid Epidemic Jeff Jacobson PharmD Southpointe Pharmacy Discuss the current opioid crisis Define the role of Naloxone in opioid overdose Analyze the barriers to
More informationProper Medication Disposal
Proper Medication Disposal MPhA 2014 Annual Conference September Disclosures I have no disclosures relative to this presentation. Carolyn O Donnell Minnesota Multistate Contracting Alliance for Pharmacy
More informationNaloxone Expanded Access: OTC status Considerations for a Nonprescription Drug Development Program
Naloxone Expanded Access: OTC status Considerations for a Nonprescription Drug Development Program Andrea Leonard-Segal, M.D., M.S. Director, Division of Nonprescription Clinical Evaluation 1 Contents
More informationOXYCONTIN Diversion & Abuse Drug Enforcement Administration Office of Diversion Control October 2003
OXYCONTIN Diversion & Abuse Office of Diversion Control October 2003 OXYCONTIN OxyContin is a controlled release form of Schedule II oxycodone Manufactured in tablet form and intended for oral ingestion
More informationUnited States For Non-Dependence: An Analysis of the Impact of Opioid Overprescribing in America
United States For Non-Dependence: An Analysis of the Impact of Opioid Overprescribing in America September 26, 2017 USND Report Background This report is the culmination of research to identify and better
More informationHow to inject op oxycontin
How to inject op oxycontin The Borg System is 100 % How to inject op oxycontin Injecting oxycontin is one of the primary methods of abusing this highly addictive prescription drug. Injecting oxycontin
More informationDoctor Shopping Behavior and the Diversion of Opioid Analgesics:
Doctor Shopping Behavior and the Diversion of Opioid Analgesics: 2008-2012 A report prepared for The Executive Office of The President Office of National Drug Control Policy Ron Simeone Simeone Associates,
More informationSubmitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis
STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite
More informationACCG Mental Health Summit
ACCG Mental Health Summit Sheila Pierce, Opioid Program Coordinator Director, Prescription Drug Management Program Discussion 1. Overview Opioid Problem in GA - Video 2. DPH Opioid Program 3. Priorities
More informationOur Core Thoughts on Dealing with the Opioid Addiction Crisis. Meghan McNelly, PharmD, MHA, FACHE Suzette Song, MD Joseph Alhadeff, MD
Our Core Thoughts on Dealing with the Opioid Addiction Crisis Meghan McNelly, PharmD, MHA, FACHE Suzette Song, MD Joseph Alhadeff, MD Outline Brief History of the Opioid Problem How did we as a medical
More informationPREVENTION. Carroll County Health Department. Bureau of Prevention, Wellness and Recovery
PREVENTION Carroll County Health Department Bureau of Prevention, Wellness and Recovery What is Prevention? Prevention is the promotion of constructive lifestyles and norms that discourage drug abuse.
More informationOpioids drive continued increase in drug overdose deaths
CDC: Drug overdose deaths increase for 11th consecutive year Opioids drive continued increase in drug overdose deaths Atlanta, GA, USA (February 20, 2013) - Drug overdose deaths increased for the 11th
More informationThe Role of Dentists in Preventing Opioid Abuse Tufts Health Care Institute Program on Opioid Risk Management 12 th Summit Meeting March 11-12, 2010
The Role of Dentists in Preventing Opioid Abuse Tufts Health Care Institute Program on Opioid Risk Management 12 th Summit Meeting March 11-12, 2010 EXECUTIVE SUMMARY It is well documented in multiple
More informationA LOOK AT ABUSE-DETERRENT OPIOIDS
JULY 2017 Drugs Under Review ICER s report reviewed evidence on ten abuse-deterrent formulations (ADF) of opioids. Nine of the drugs were extended release (ER) opioids, and one was immediate release (IR).
More informationAbuse of opioid painkillers in the US is a major problem
As appeared in January 2018 Tablets & Capsules www.tabletscapsules.com formulation Abuse-deterrent formulation technologies: Opportunities and limitations Alyn McNaughton Lonza Too many Americans are misusing
More informationTHE FDA DRUG APPROVAL PROCESS Under the Federal Food, Drug, and Cosmetic (FD&C) Act, FDA is responsible for ensuring that all new drugs are safe and
THE FDA DRUG APPROVAL PROCESS Under the Federal Food, Drug, and Cosmetic (FD&C) Act, FDA is responsible for ensuring that all new drugs are safe and effective. Before any drug is approved for marketing
More informationUnderstanding the US Opioid Analgesic Market
Understanding the US Opioid Analgesic Market Key Trends & Market Snapshot December 2017 Purdue Pharma L.P. provided funding and content review for this report. Avalere Health maintained full editorial
More informationEXECUTIVE ORDER TAKING FURTHER ACTIONS TO ADDRESS THE OPIOID OVERDOSE CRISIS
EXECUTIVE ORDER TAKING FURTHER ACTIONS TO ADDRESS THE OPIOID OVERDOSE CRISIS Gina M. Raimondo, Governor Nicole Alexander-Scott, MD, MPH, Director of Health Action Plan Strategies to Date Since 2015, we
More informationThe Challenge of Treating Pain
FDA Charge to the Committee: FDA Opioid Action Plan and Incorporating the Broader Public Health Impact into the Formal Risk-Benefit Assessment for Opioids Robert M. Califf, MD Commissioner of Food and
More informationPrescription Drug Safety for Teens
Prescription Drug Safety for Teens Curriculum Guide Recommended Grade Level 9-12 Total Time 30-45 minutes Subject Fit Health Standards Alignment National Health Education Standards (NHES) With prescription
More informationSchedules of Controlled Substances: Temporary Placement of Furanyl Fentanyl. AGENCY: Drug Enforcement Administration, Department of Justice
This document is scheduled to be published in the Federal Register on 09/27/2016 and available online at https://federalregister.gov/d/2016-23183, and on FDsys.gov Billing Code 4410-09-P DEPARTMENT OF
More informationCSS Perspective - Opioid Risk Management
Tufts Health Care Institute Program on Opioid Risk Management Risk Evaluation and Mitigation Strategy for Prescription Opioids: An In-Depth Review of Fundamental Issues CSS Perspective - Opioid Risk Management
More informationA National Perspective on the Abuse and Diversion of Prescription Drugs
A National Perspective on the Abuse and Diversion of Prescription Drugs Hilary L. Surratt, Ph.D Steven P. Kurtz, Ph.D. ARSH: Center for Applied Research on Substance Use and Health Disparities Faculty
More informationRegulating Physician Dispensing. Evidence From WCRI Studies
Regulating Physician Dispensing Evidence From WCRI Studies Current Public Policies Most states permit physician dispensing 8 states physician dispensing rare or not allowed because of legal barriers Most
More informationFDA s Response to the Opioid Crisis and the FDA Safe Use Initiative
FDA s Response to the Opioid Crisis and the FDA Safe Use Initiative Scott K. Winiecki, MD Professional Affairs and Stakeholder Engagement Staff (PASES) Center For Drug Evaluation and Research (CDER) U.S.
More informationEducation & Exhibit Center. Opening Eyes to Drugs: The Damaging Effects
Education & Exhibit Center Opening Eyes to Drugs: The Damaging Effects Letter from Gail and David Katz and Melissa Katz Gold Founding Directors, SAVE A STAR Drug Awareness Foundation The SAVE A STAR Drug
More informationFentanyl, Opioid Overdose and Naloxone
Fentanyl, Opioid Overdose and Naloxone Opioid Agonist Therapy Conference Saskatoon, SK April, 2016 Declaration No conflict of interest. Consultant in Addiction Medicine, SHR. Chair, College of Physicians
More informationShining a Light on MEDs Understanding morphine equivalent dose
Shining a Light on MEDs Understanding morphine equivalent dose In the workers compensation industry, 60.2 percent of claimants utilize opioid analgesics for the treatment of pain caused by a workplace
More informationLand O Lakes Blvd S.R. 52. Veteran s Expy U.S Pasco Sheriff s Office (727) (West Operations Center) M-F 7432 Little Road
Veteran s Expy Pasco County U.S. 19 Unused or expired medications are often flushed down a drain or end up in the wrong hands. Help protect our environment and the health of our community. Please dispose
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event
More informationWhat is drug diversion?
Learning Objectives Identify the impact of drug diversion on patients and healthcare organizations Explain the common points of risks and methods of drug diversion in healthcare s controlled substance
More informationCardinal Health s Commitment to Opioid Anti-Diversion, Education and Misuse Prevention
Cardinal Health s Commitment to Opioid Anti-Diversion, Education and Misuse Prevention The people of Cardinal Health care deeply about the devastation opioid abuse has caused American families and communities
More informationWHAT YOU NEED TO KNOW TO ABOUT AB 474
WHAT YOU NEED TO KNOW TO ABOUT AB 474 PRESENTED BY: NEVADA STATE BOARD OF OSTEOPATHIC MEDICINE 2275 Corporate Circle, Suite 210 Henderson, NV 89074 702-732-2147 Fax 702-732-2079 Web Site: www.bom.nv.gov
More informationSetting the Stage: Are Abuse-Deterrent Opioids Formulations Ready for Prime Time?
Setting the Stage: Are Abuse-Deterrent Opioids Formulations Ready for Prime Time? Lewis S. Nelson, MD New York University School of Medicine New York City Poison Control Center Opioid Abuse Liability
More informationDan Cohen Forum Chair - Abuse DeterrentCoalition. Abuse Deterrent Formulations of Opioids and the Abuse Deterrent Coalition
Dan Cohen Forum Chair - Abuse DeterrentCoalition Abuse Deterrent Formulations of Opioids and the Abuse Deterrent Coalition Prescription Drug Abuse and Diversion Partnering with Law Enforcement, Anti-Drug
More informationPrescription Drug Abuse National Perspective
Prescription Drug Abuse National Perspective Timothy P. Condon, Ph.D. Science Policy Advisor Office of the Director White House Office of National Drug Control Policy Commonly Abused Prescription Drugs
More informationPrescription Medication Guidelines for Medical Providers in CorVel s CorCare and Care IQ Networks
Prescription Medication Guidelines for Medical Providers in CorVel s CorCare and Care IQ Networks Patient Health and Safety Guidelines Prescription Medications Policy Update / April 2017 In connection
More informationMethadone. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.41 Subject: Methadone Page: 1 of 8 Last Review Date: March 18, 2016 Methadone Description Dolophine
More informationNucynta IR/ Nucynta ER (tapentadol immediate-release and extendedrelease)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Nucynta Page: 1 of 7 Last Review Date: March 18, 2016 Nucynta Description Nucynta IR/ Nucynta
More informationStrategies to Manage The Opioid Crisis
Strategies to Manage The Opioid Crisis Matt Feehery, LCDC Senior Vice President & CEO PaRC (Prevention & Recovery Center) Behavioral Health Services February 1, 2018 A Pill for Your Pain But my doctor
More informationSafe Disposal in Colorado: A State-Led Approach
Safe Disposal in Colorado: A State-Led Approach WELCOME! PDMP TTAC Webinar February 21, 2018 Safe Disposal in Colorado: A State-Led Approach Presenters Greg Fabisiak, Environmental Integration Coordinator,
More informationAppearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse
Opening Statement Appearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse Dr. Chris Simpson, President-elect
More informationSafe Disposal of Unneeded Medications
Safe Disposal of Unneeded Medications Lesson created by: Marilyn Sink Molly Marshall Health & Human Sciences Educator/CED Health & Human Sciences Educator Clark County, Area 2 Jackson County, Area 2 msink@purdue.edu
More informationSeptember 1, The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201
September 1, 2017 The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Dear Secretary Price: The National Association of County
More informationDevelopment of Abuse- Resistant Opioid Formulations
Development of Abuse- Resistant Opioid Formulations William K. Schmidt, PhD VP, Clinical Research, Renovis, Inc. Opioid Risk Management, March 29, 2005 Mrs Winslow's Soothing Syrup For children teething.
More informationPrescription Opioid Dependence and Addiction: Experience in the United States
Prescription Opioid Dependence and Addiction: Experience in the United States September 27, 2013 Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center Professor, University of Colorado
More informationDocuments Regarding Drug Abuse Assessments
Overview of the FDA Guidance Documents Regarding Drug Abuse Assessments ABUSE DETERRENT FORMULATION SCIENCE MEETING DISCUSSION OF THE FDA DRAFT GUIDANCE FOR INDUSTRY: ABUSE DETERRENT OPIOIDS EVALUATION
More informationChanges to the Eighth Edition
Pharmacy Practice and the Law, Eighth Edition Includes Navigate 2 Advantage Access By Richard R. Abood, BS Pharm, JD-Professor Emeritus Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences,
More informationThe Difficult Patient: Risk Mitigation Strategies
The Difficult Patient: Risk Mitigation Strategies C. Scott Anthony, D.O. Pain Management of Tulsa 1 Opioid Backlash National emergency Opioids not indicated for chronic pain Forces pushing for reduction
More informationINFORMATION BRIEF. Overview. Prescription Drug Abuse Among Young People
Product No. 2002-L0424-004 INFORMATION BRIEF AUGUST 2002 U. S. D E P A R T M E N T O F J U S T I C E Overview Prescription drugs, a category of psychotherapeutics that comprises prescription-type pain
More information2004-L SEPTEMBER
BULLETIN INTELLIGENCE Buprenorphine: Potential for Abuse Product No. 2004-L0424-013 SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E NDIC Within the past 2 years buprenorphine a Schedule III
More informationFundamentals of Pharmacology
West Los Angeles College Worksheet #1 Fundamentals of Pharmacology Multiple Choice Identify the choice that best completes the statement or answers the question. 1. By which of the following routes are
More informationGuideline for the Rational Use of Controlled Drugs
Guideline for the Rational Use of Controlled Drugs Ministry of Health Male' Republic of Maldives April 2000 Table of Contents Page Introduction.. 2 1. Procurement and Supply of Controlled Drugs 3 1.1 Import
More informationAnyone Can Become Addicted. Anyone.
Anyone Can Become Addicted. Anyone. PAStop.org Family Toolkit Seeking Drug Abuse Treatment: Know What to Ask Trying to identify the right treatment programs for a loved one can be a difficult process.
More informationUNIVERSITY POLICY. Revised: Contact:
UNIVERSITY POLICY Policy Name: Policy for Controlled Substances Section #: 90.2.3 Section Title: Compliance Approval Authority: Responsible Executive: Responsible Office: Formerly Book: President Adopted:
More informationChapter 1: Fundamentals of Pharmacology Test Bank
Chapter 1: Fundamentals of Pharmacology Test Bank MULTIPLE CHOICE 1. By which of the following routes are drugs administered directly into the bloodstream? a. Enteral b. Transdermal c. Transmucosal d.
More informationIntroduction. Ethical Impact Analysis
Introduction As an ethical and responsible engineer, when designing any product, it is important to consider the impacts that it may have on its users and the world around us, both in normal use, and when
More informationGabapentin diversion and misuse in the United States from a law enforcement perspective: Diversion rates and qualitative research findings
Gabapentin diversion and misuse in the United States from a law enforcement perspective: Diversion rates 2002-2015 and qualitative research findings Mance E. Buttram, PhD Steven P. Kurtz, PhD 2 nd European
More informationPrescription Drug Monitoring Program Update. Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017
Prescription Drug Monitoring Program Update Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017 Objectives Brief historical overview of opioids Review of PDMP information Discuss ideas from
More informationEDUCATIONAL COMMENTARY METHADONE
EDUCATIONAL COMMENTARY METHADONE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits see the Continuing Education
More informationSTATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A.
STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A. Arizona Corporate Counsel Presentation May 8, 2018 Agenda 1. Overview of the Opioid
More informationOttawa Public Health Pam Oickle Sarah Archer
Ottawa Public Health Pam Oickle Sarah Archer Pam Oickle Supervisor, Site Needle & Syringe Program Public Health Nurse 15 years Sarah Archer Public Health Nurse, Site Needle & Syringe Program 3 years Pamela.Oickle@Ottawa.ca
More informationGOVERNMENT S ROLE IN ADDRESSING PRESCRIPTION DRUG ABUSE
POSITION PAPER GOVERNMENT S ROLE IN ADDRESSING PRESCRIPTION DRUG ABUSE Governments across Canada are concerned about the abuse of prescription drugs, with recent policy discussions focused on mitigating
More informationOpioid Deaths Quadruple Since 1999
THE COUNCIL OF STATE GOVERNMENTS CAPITOL RESEARCH AUGUST 2017 HEALTH POLICY Opioid Deaths Quadruple Since 1999 Since 1999, the number of overdose deaths involving opioids (including prescription opioids
More informationChallenges for U.S. Attorneys Offices (USAO) in Opioid Cases
Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases Overview On August 2, 2017, U.S. Attorney General Jeff Sessions announced a pilot program whereby a new federal data analysis program is being
More informationNDA MF REMS ASSESSMENT ACKNOWLEDGMENT
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 REMS ASSESSMENT ACKNOWLEDGMENT Insys Development Co. c/o Insys Therapeutics, Inc. 1333 South Spectrum Blvd.,
More informationTitan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event
More informationPREVENTING OPIATE OVERDOSES IN SCHOOLS. Head 2 Toe 2017 April 20, 2017 Winona Stoltzfus BSN, MD, School Health Officer and Acting RHO SE Region
PREVENTING OPIATE OVERDOSES IN SCHOOLS Head 2 Toe 2017 April 20, 2017 Winona Stoltzfus BSN, MD, School Health Officer and Acting RHO SE Region WHY IS THIS EVEN A QUESTION FOR SCHOOLS? In 2014, 467,000
More informationOn December 27, 2017, the Lieutenant Governor signed into law several new requirements
OPIOID Alert MICHIGAN OSTEOPATHIC ASSOCIATION JANUARY 2018 On December 27, 2017, the Lieutenant Governor signed into law several new requirements aimed at combating the opioid epidemic. On the following
More informationOPIOID SAFE- PRESCRIBING TRAINING IMMERSION (OSTI)
OPIOID SAFE- PRESCRIBING TRAINING IMMERSION (OSTI) Case 1- Prep Materials University of Massachusetts Medical School Opioid Conscious Curriculum March 2018 Learner Prep Objectives The purpose of this prep
More informationInvestors Update: Abuse-Deterrent d-amphetamine Immediate Release (ADAIR) for ADHD
Investors Update: Abuse-Deterrent d-amphetamine Immediate Release (ADAIR) for ADHD February 7, 2017 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning
More informationPharmaceutical Fentanyl s (PF) Role in Fentanyl- related Overdose Deaths
Pharmaceutical Fentanyl s (PF) Role in Fentanyl- related Overdose Deaths Paper presented at the 2018 annual meetings of the American Public Health Association, San Diego, CA Session 5061.0: Impact of fentanyl
More informationTitan Pharmaceuticals Overview
Corporate Presentation July 2014 1 Safe Harbor The presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
More informationOVERVIEW OF PRESENTATION
OVERVIEW OF PRESENTATION Trends Methodology Key messages from public consultation Vision Values, Goals, s Performance Measurement System Health-led actions Structures supporting delivery DRUG AND ALCOHOL
More informationChanging Prescribing Practices In Dentistry
Changing Prescribing Practices In Dentistry Paul J. Desjardins, D.M.D., Ph.D. Adjunct Clinical Professor, Rutgers School of Dental Medicine Visiting Professor, Tufts University, School of Dental Medicine
More informationOnline Appendix. Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids
Online Appendix Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids Abby Alpert, David Powell, Rosalie Liccardo Pacula Appendix Figure A.1:
More informationPrescription Drug Monitoring Program (PDMP)
Prescription Drug Monitoring Program (PDMP) District of Columbia Information contained in this presentation is accurate as of September 2017 Meet the Speaker Tadessa Harper-Nichols Program Specialist Pharmaceutical
More informationSafe Medication Disposal A white position paper Pennsylvania Pharmacists Association February 8, 2009
Safe Medication Disposal A white position paper Pennsylvania Pharmacists Association February 8, 2009 Background and Situation Analysis: Consumers are rightly confused about what to do with their unwanted
More informationMedia Kit. September 2017
Media Kit September 2017 About Pear Pear Therapeutics is the leader in FDA-cleared Prescription Digital Therapeutics. The company s approach is to integrate clinically-validated software applications with
More informationAddiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer
Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South
More informationWORKING UPSTREAM TO COMBAT THE OPIOID CRISIS
WORKING UPSTREAM TO COMBAT THE OPIOID CRISIS WELCOME Kate Gainer, PharmD Executive Vice President and CEO Iowa Pharmacy Association PRESENTER Sarah Derr, PharmD Medication Management Lead Iowa Healthcare
More informationTrends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville
Trends and Challenges: The Kentucky Opioid Crisis Jason Smith, MD PhD University of Louisville Brief Introduction I am by no means an expert I have no financial disclosures Jokes are meant to be lighthearted
More informationFORMULATION DEVELOPMENT - A QbD Approach to Develop Extended Release Softgels
Seite 1 von 8 Share this story: Issue: April 2015, Posted Date: 3/30/2015 FORMULATION DEVELOPMENT - A QbD Approach to Develop Extended Release Softgels INTRODUCTION Soft gelatin capsules (softgels) continue
More information9/3/2013. Presentation Objective. Prescription Drug Abuse Statistics Prescription Drug Abuse Statistics. Pharmaceutical Drugs and the Environment
Presentation Objective Background - Why do we need a regulation for the disposal of controlled substances. Disposal of Controlled Substances DEA Notice of Proposed Rulemaking AHMP 2013 National Conference
More informationOpioid Policy Steering Committee: Prescribing Intervention--Exploring a Strategy for
This document is scheduled to be published in the Federal Register on 12/13/2017 and available online at https://federalregister.gov/d/2017-26785, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More information2016 Drug Trends Series
Drug Trends Series Part 3: Assessing opioids and compounds Published August 2017 1 Drug Trends Series Opioids & Compounds First Script Introduction As with the first two editions in Coventry s Drug Trends
More information